Supplementary

					-
T 11 C1 D'CC 1	1 . C 11 11 .	1 1 1	• • • • •	C 11 CC	
able SI I litterential a	analyzers of call adhese	on related nothway	to in two cluctore of	dittorontial av	processon of mil regulators
	111111111111111111111111111111111111111	UII-I CIALCU DALIIWAV		uniterential ex	$D_1 \in S_1 \cup H \cup H \cup H \cup H \in U \cap U$

Pathway	LogFC	t	AveExpr	P value	
Cytokine-cytokine receptor interaction	-0.16196	-0.00389	-9.37677	199E-19	
Wnt signaling pathway	-0.23423	0.01348	-6.51917	165E-10	
MAPK signaling pathway	0.062457	0.004033	4.24067	2.63E-05	
Actin binding	0.050517	0.003888	3.384926	0.000765	
Focal adhesion	-0.05199	0.001442	-2.68443	0.007493	
Integrin binding	0.062623	0.003874	2.574798	0.010301	
Tight junction	0.020722	0.009876	1.35289	0.176669	
Regulation of actin cytoskeleton	-0.01534	-0.0058	-0.77599	0.438102	
Cell-substrate adhesion	0.004211	0.003562	0.222486	0.824022	



Figure S1 (A) consensus matrix at k=3-6. (B-Q) Kaplan-Meier overall survival curves for the remaining sixteen representative genes.

	2	0				
Characteristics		Univariate analys	Univariate analysis		Multivariate analysis	
	10tal (N) —	HR (95% CI)	P value	HR (95% CI)	P value	
NOP2	551	1.233 (0.839–1.814)	0.287			
NSUN2	551	1.997 (1.340–2.974)	<0.001	1.594 (0.935–2.718)	0.087	
NSUN3	551	1.584 (0.928–2.703)	0.092	1.183 (0.568–2.464)	0.654	
NSUN4	551	1.711 (1.037–2.823)	0.035	1.015 (0.546–1.886)	0.962	
NSUN5	551	1.390 (0.901–2.145)	0.137			
NSUN6	551	1.230 (0.788–1.921)	0.363			
NSUN7	551	0.968 (0.711–1.318)	0.837			
ALKBH1	551	0.869 (0.544–1.388)	0.557			
TRDMT1	551	1.395 (0.855–2.276)	0.183			
TET1	551	1.386 (0.963–1.995)	0.079	1.065 (0.631–1.798)	0.813	
TET2	551	0.931 (0.621–1.396)	0.728			
TET3	551	1.492 (1.056–2.107)	0.023	1.066 (0.630–1.803)	0.812	
ALYREF	551	1.572 (1.090–2.268)	0.015	1.217 (0.762–1.944)	0.411	
YBX1	551	1.305 (1.017–1.674)	0.037	1.095 (0.791–1.515)	0.585	

Table S2 Univa	riate Cox analy	sis of 14 m ⁵ C	regulators in	UCEC
	inface oon analy	010 01 1 1 111 0	regulators m	COLO

UCEC, uterine corpus endometrial carcinoma.